Connect with us

Politics

DEA Faces Second Lawsuit From More Medical Marijuana Businesses That Say Rescheduling Rules Could Upend State Markets

Published

on

A second group of medical cannabis businesses are suing the Drug Enforcement Administration (DEA) over restrictions the agency is placing on marijuana businesses in conjunction with the Trump administration’s federal rescheduling move that industry observers and regulators believe could upend state-licensed markets.

The latest challenge comes from four vertically integrated medical cannabis companies that say the DEA rules will prevent their dispensaries from selling products that their own cultivators grow.

Last month, DEA announced it had granted federal registration and protections to hundreds of medical marijuana businesses in line with rescheduling while also issuing new guidance warning that cannabis companies have until November 29 to begin sourcing product only from and to other operators that have also been granted or applied for registration in a timely fashion.

On Thursday, four companies that operate vertically integrated cultivation, processing and dispensary businesses in Pennsylvania filed a lawsuit asking the U.S. Court of Appeals for the District of Columbia Circuit to put a stay on the new DEA restrictions.

The companies—G.P.M.II, LLC, MLH Explorations LLC, Tri-Mountain Pure, LLC, and Story of PA CR, LLC—argue that DEA’s staggered rollout of forms to register medical marijuana dispensaries and manufacturers for federal protections caused “industry confusion” and ultimately did not give integrated businesses like theirs enough time or sufficient guidance to apply to receive expedited consideration of the cultivation divisions of their operations.

As a result of the recently issued DEA guidance, the companies’ dispensaries will not be able to sell the medical marijuana that their own cultivation employees are growing under state law, they say.

“Petitioners applied early—within 60 days of the rescheduling order—to register their dispensaries. They did not apply to register their manufacturing operations due to inconsistent and confusing direction from DEA. As a result, under new guidance issued by DEA on October 30, 2026, Petitioners’ manufacturing divisions will be barred from supplying any entity that is federally registered or that applied for registration during the 60-day window— including their own dispensaries—as of November 29, 2026.”

The DEA’s stance will “generate massive disruption by forcing early applicants (like Petitioners) to overhaul supply chains in a few short weeks, and shutting down facilities (like Petitioners’ manufacturing divisions) that lack early-applicant status,” the petition says. “Patients who rely on medical marijuana to treat chronic and debilitating conditions will bear the cost.”

Unless the court pauses the agency’s move within a matter of days, “the results will be devastating—for Petitioners’ businesses and reputations, for the many individuals they employ, and for the countless patients they serve,” the companies’ lawyers wrote.

“The counterparty restriction will upend Petitioners’ businesses. Their manufacturing arms stand to lose hundreds of thousands of dollars in monthly revenue from third-party-dispensary sales alone. And Petitioners’ dispensaries will be forced to buy from competitor manufacturers (if they are even able to locate sufficient supply)—or cease operations. Even if Petitioners somehow continue operating, they will be forced to take irreversible steps, including closing facilities and laying off employees.”

GPM is the parent company of the multi-state operator INSA, and Story’s parent company is Ascend Wellness Holdings, which also operates businesses in multiple states. MLH Explorations and Tri-Mountain Pure and their parent companies only operate in Pennsylvania.

A day earlier, the companies Standard Wellness Utah, Verde Americano in Arizona and NW Confections OK in Oklahoma brought a separate suit challenging the DEA medical cannabis guidance. The two cases have now been consolidated by the court and will be considered together.

The DEA’s guidance, the new Pennsylvania-focused petition argued, must be stayed because it is procedurally deficient, contrary to law and arbitrary and capricious.

“A later victory would come too late,” they said. “Even if DEA ultimately grants Petitioners federal registrations, the harm will be done.”

Among other claims, the petition says DEA failed to go through required notice and comment rulemaking for the new rules.

Meanwhile, DEA has been refusing to grant federal registration and protections to medical marijuana businesses in at least six states and Washington, D.C.

In orders to show cause sent to applicants in California, Delaware, the District of Columbia, Illinois, Minnesota, North Dakota and Oregon, the agency has cited various provisions of those states’ laws as reasons it cannot register any business within those jurisdictions.

Although the documents differ from state to state, there are similarities, according to industry sources who have reviewed the orders, the text of some of which have been shared with Marijuana Moment.

For example, the DEA orders generally cite some of the states’ allowance of businesses to sell non-medical marijuana as a violation of the Controlled Substances Act’s (CSA) “closed system” for medical access to scheduled drugs and of the U.S.’s international treaty obligations.

Some of the documents also single out state laws that allow certain patients to access medical cannabis without a doctor’s written recommendation.

State cannabis regulators have expressed frustrations with the agency’s actions and general refusal to communicate with them about its plans.

The Cannabis Regulators Association’s Gillian Schauer—who represents state officials across the U.S.—argued in a recent Marijuana Moment op-ed that the way DEA is implementing rescheduling has “created deep uncertainty and disruption for regulators, patients and market operators” and came with “little or no advance notice to state regulators and minimal communication afterward.”

“Supply chains in many states will not have enough cultivators, manufacturers and dispensaries to support a viable supply chain in either the DEA market or the state-only market,” she wrote. “With bifurcated and incomplete supply chains in states, some businesses will not survive in either market, patient access will be impacted, diversion and inversion will become more difficult for regulators to detect, health and safety compliance will be eroded and state revenues that support a variety of public services will decrease.”

Read the new lawsuit against the DEA below:

Photo elements courtesy of rawpixel and Philip Steffan.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Become a patron at Patreon!

Tom Angell is the editor of Marijuana Moment. A 25-year veteran in the cannabis and drug law reform movement, he covers the policy, politics, science and culture of marijuana, psychedelics and other substances. He previously reported for Forbes, Marijuana.com and MassRoots, and was given the Hunter S. Thompson Media Award by NORML and has been named Journalist of the Year by Americans for Safe Access. As an activist, Tom founded the nonprofit Marijuana Majority and handled media relations, campaigns and lobbying for Law Enforcement Against Prohibition and Students for Sensible Drug Policy.

Advertisement

Marijuana News In Your Inbox

Get our daily newsletter.

Support Marijuana Moment

Add Marijuana Moment as a preferred source on Google.

Marijuana News In Your Inbox

 

Get our daily newsletter.